Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

Authors

  • Roberto Ravasio Health Publishing & Services Srl, Milan - Italy
  • Antonio Costanzo Dermatology, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan and Dermatology, IRCCS Humanitas Research Hospital, Rozzano, Milan - Italy
  • Silvia Antonelli Eli Lilly Italia S.p.A., Sesto Fiorentino - Italy
  • Alessia Maiorino Eli Lilly Italia S.p.A., Sesto Fiorentino - Italy
  • Serena Losi Eli Lilly Italia S.p.A., Sesto Fiorentino - Italy

DOI:

https://doi.org/10.33393/grhta.2021.2222

Keywords:

Interleukin inhibitor, Ixekizumab, Number needed to treat, Plaque psoriasis

Abstract

Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis.

Methods: The clinical efficacy was evaluated in terms of NNT, based on the results of a recent network meta-analysis (NMA) by the Cochrane Database of Systematic Reviews. The NMA investigated many systemic and biological treatments, but this analysis compared only the efficacy of the following IL inhibitors – brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab – for patients with moderate-to-severe plaque psoriasis. Drugs were compared and ranked according to effectiveness considering the PASI (Psoriasis Area and Severity Index) 90 score.

Results: One-hundred and forty trials (51,749 patients) were included in the NMA. Considering the proportion of patients who achieve PASI90, ixekizumab showed the lowest NNT among all comparators (ixekizumab 2.01 [2.46-3.00]; risankizumab 2.05 [2.50-3-05]; guselkumab 2.16 [2.68-3.36]; secukinumab 2.40 [2.90-3.51]; brodalumab 2.61 [3.18-3.88]; ustekinumab 3.44 [4.12-4.95]; tildrakizumab 3.10 [4.15-5.59].

Conclusion: The findings show that ixekizumab is the most effective option (NNT) for the treatment of moderate-to-severe plaque psoriasis.

References

  1. Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016;3(1):79-82. PMID:28058392
  2. World Health Organization. Psoriasis: Report by the Secretariat. 2013; http://apps.who.int/gb/ebwha/pdf_files/EB133/B133_5-en.pdf. Accessed January 13, 2016.
  3. Elder JT, Bruce AT, Gudjonsson JE, et al. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol. 2010;130(5):1213-1226. https://doi.org/10.1038/jid.2009.319PMID:19812592
  4. Jariwala SP. The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res. 2007;299(8):359-366. https://doi.org/10.1007/s00403-007-0775-4 PMID:17680257
  5. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-1211. https://doi.org/10.1038/sj.jid.5701213 PMID:18200064
  6. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895. PMID:20713823
  7. Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol. 2008;22(3):324-329. https://doi.org/10.1111/j.1468-3083.2007.02423.xPMID:18269600
  8. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493-1499. https://doi.org/10.1001/archderm.143.12.1493 PMID:18086997
  9. Naldi L, Colombo P, Placchesi EB, et al. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology. 2004;208:38-42. https://doi.org/10.1159/000075044 PMID 14730235
  10. Vena GA, Altomare G, Ayala F, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol. 2010;20(5):593-598. PMID:20605768
  11. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. https://doi.org/10.1016/S0140-6736(14)61909-7 PMID:26025581
  12. Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. https://doi.org/10.1101/cshperspect.a015354 PMID:25085957
  13. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. https://doi.org/10.1016/j.jaad.2008.02.039 PMID:18423260
  14. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60(3):394-401. https://doi.org/10.1016/j.jaad.2008.10.062 PMID:19231638
  15. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(suppl 2):1-70. https://doi.org/10.1111/j.1468-3083.2009.03389.x PMID:19712190
  16. Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774-790. https://doi.org/10.1111/jdv.14114 PMID:28244153
  17. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. Clin Dermatol. 2010;28(1):67-72. https://doi.org/10.1016/j.clindermatol.2009.03.001 PMID:20082954
  18. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943. https://doi.org/10.1038/jid.2009.391 PMID:20043014
  19. Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):CD011535. https://doi.org/10.1002/14651858.CD011535.pub3 PMID:31917873
  20. Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645-648. https://doi.org/10.1111/jdv.12817 PMID:25370811
  21. Strober B, Papp KA, Lebwohl M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016;75(1):77-82.e7. https://doi.org/10.1016/j.jaad.2016.03.026PMID:27206759
  22. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318(26):1728-1733. https://doi.org/10.1056/NEJM198806303182605 PMID:3374545
  23. Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med. 2017;15(1):112. https://doi.org/10.1186/s12916-017-0875-8PMID:28571585
  24. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-454. https://doi.org/10.1136/bmj.310.6977.452 PMID:7873954
  25. Altman DG, Schulz KF, Moher D, et al; CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663-694. https://doi.org/10.7326/0003-4819-134-8-200104170-00012 PMID:11304107
  26. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(Mar23 1):c869. https://doi.org/10.1136/bmj.c869 PMID:20332511
  27. Hildebrandt M, Vervölgyi E, Bender R. Calculation of NNTs in RCTs with time-to-event outcomes: a literature review. BMC Med Res Methodol. 2009;9(1):21. https://doi.org/10.1186/1471-2288-9-21 PMID:19302699
  28. Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA. 2002;287(21):2813-2814. https://doi.org/10.1001/jama.287.21.2813 PMID:12038920
  29. Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, et al. Systematic reviews experience major limitations in reporting absolute effects. J Clin Epidemiol. 2016;72:16-26. https://doi.org/10.1016/j.jclinepi.2015.11.002 PMID:26560992
  30. Citrome L. Relative vs. absolute measures of benefit and risk: what’s the difference? Acta Psychiatr Scand. 2010;121(2):94-102. https://doi.org/10.1111/j.1600-0447.2009.01449.xPMID:19694632
  31. Straus SE, Glasziou P, Richardson WS, Haynes RB. Evidence-based medicine: how to practice and teach it. London: Churchill Livingstone; 2011.
  32. Citrome L, Ketter TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407-411. https://doi.org/10.1111/ijcp.12142 PMID:23574101
  33. Mt-Isa S, Hallgreen CE, Wang N, et al; IMI-PROTECT benefit-risk participants. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Pharmacoepidemiol Drug Saf. 2014;23(7):667-678. https://doi.org/10.1002/pds.3636PMID:24821575
  34. Mendes D, Alves C, Batel-Marques F. Number needed to harm in the post-marketing safety evaluation: results for rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 2015;24(12):1259-1270. https://doi.org/10.1002/pds.3874 PMID:26376779
  35. Mendes D, Alves C, Batel Marques F. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Expert Opin Drug Saf. 2016;15(10):1301-1312. https://doi.org/10.1080/14740338.2016.1217989 PMID:27467204
  36. Greco T, Biondi-Zoccai G, Saleh O, et al. The attractiveness of network meta-analysis: a comprehensive systematic and narrative review. Heart Lung Vessel. 2015;7(2):133-142. PMID:26157739
  37. Greco T, Landoni G, Biondi-Zoccai G, D’Ascenzo F, Zangrillo A. A Bayesian network meta-analysis for binary outcome: how to do it. Stat Methods Med Res. 2016;25(5):1757-1773. https://doi.org/10.1177/0962280213500185 PMID:23970014
  38. Hartz SDY, Kiri SH, Schacht A, Walzer S, Dakin H. Network meta-analysis to evaluate the efficacy of ixekizumab in the treatment of moderate-to-severe psoriasis. (Poster). International Society for Pharmacoeconomics and Outcomes (ISPOR), 19th Annual European Congress; 2016.
  39. Núñez M, Huete T, de la Cueva P, Sacristán JA, Hartz S, Dilla T. A cost-per-number needed to treat analysis assessing the efficiency of biologic drugs in moderate to severe plaque psoriasis. Actas Dermosifiliogr. 2019;110(7):546-553. https://doi.org/10.1016/j.adengl.2019.07.001 PMID:30851873

Most read articles by the same author(s)

<< < 1 2 3 4 > >>